Casdin Capital
VC Fund
New York, United States
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
- Total investments:
- 221
- Last investment:
- Lead investor:
- 17%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Casdin Capital invests in
Stages Casdin Capital invests in
Countries Casdin Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $10M–$200M
- Series B
- $32M–$150M
- Series C
- $35M–$175M
Investment Focus
Industry
- Biotechnology 122 (55%)
- Health Care 80 (36%)
- Therapeutics 47 (21%)
- Medical 37 (17%)
- Life Science 31 (14%)
Stage
- Series B 56 (25%)
- Series A 43 (19%)
- Series C 33 (15%)
- Post-IPO Equity 18 (8%)
- Series D 12 (5%)
Country
- United States 121 (55%)
- China 5 (2%)
- France 5 (2%)
- United Kingdom 4 (2%)
- Canada 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Suzanne Angell
Director of Research
|
Director of Research | Total investments: 1 | Find email | |
Eli Casdin
managing partner
|
managing partner | Total investments: 28 | Find email | |
John Graziano
Platform Investor Relations & Syndication Lead
|
Platform Investor Relations & Syndication Lead | Total investments: 0 | Find email | |
| CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
City Therapeutics
|
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | |
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | |
|
Adlai Nortye
|
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $140M / Post-IPO Equity / Feb 03, 2026 | |
Apella Technology
|
Apella is an AI startup that brings modern engineering to improve surgery. It collects data from operating rooms in hospitals via sensors and puts artificial intelligence to the task of analyzing that information and spits it out in a way that that the startup says can be interpreted by hospitals to improve operations, surgical quality, training,and even real-time decision-making.Apella was founded in 2019 and is headquartered in San Francisco, California. | $80M / Series B / Jan 07, 2026 | |
Beacon Biosignals
|
Beacon Biosignals is a neurotechnology company focused on bringing precision neuroscience into clinical trials and treatments for brain- and sleep-related disorders. The company’s core offering includes an FDA-cleared wearable device (the Waveband headband) that captures high-fidelity EEG during sleep and wake states, combined with an AI-drivenanalytics platform that processes millions of hours of neural data to extract biomarkers of brain function. Its end-to-end solution supports pharmaceutical and biotech clients by providing tools for patient stratification, dose-response monitoring, and early-stage disease progression, enabling trials to be more precise and efficient. | $86M / Series B / Nov 13, 2025 | |
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Treeline Biosciences
|
Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT. | $200M / Series A / Sep 03, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Leyden Labs
|
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $70M / Series B / Jan 09, 2025 | |
| See all 221 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Casdin Capital invest in?
Casdin Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 221 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Casdin Capital's check size?
Casdin Capital typically joins rounds of $10M–$200M at Series A, $32M–$150M at Series B and $35M–$175M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Casdin Capital participates in.
How do I contact Casdin Capital?
Public channels for Casdin Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Casdin Capital?
The team at Casdin Capital includes Suzanne Angell (Director of Research), Eli Casdin (managing partner) and John Graziano (Platform Investor Relations & Syndication Lead). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
